Published in Cancer Lett on November 09, 2006
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol (2014) 1.81
Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol (2011) 1.39
Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics (2011) 1.33
Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol (2008) 1.22
Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg (2012) 1.22
Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma. Ann Surg (2009) 1.17
K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol Cancer Res (2009) 1.06
Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist (2010) 1.06
Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol (2011) 1.02
Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res (2013) 1.00
Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Hum Pathol (2011) 0.99
Molecular pathways in pancreatic carcinogenesis. J Surg Oncol (2012) 0.95
Next generation sequencing improves the accuracy of KRAS mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. PLoS One (2014) 0.93
Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer (2012) 0.93
Molecular Biologic Approach to the Diagnosis of Pancreatic Carcinoma Using Specimens Obtained by EUS-Guided Fine Needle Aspiration. Gastroenterol Res Pract (2012) 0.89
Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clin Cancer Res (2011) 0.89
Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas (2008) 0.89
Precursor lesions for sporadic pancreatic cancer: PanIN, IPMN, and MCN. Biomed Res Int (2014) 0.88
Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg (2014) 0.88
Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 0.87
Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Pancreas (2012) 0.86
Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis. Cancer Metastasis Rev (2013) 0.82
Intraductal papillary mucinous neoplasm of the pancreas: an update. Scientifica (Cairo) (2012) 0.81
Intraductal papillary-mucinous neoplasia of the pancreas: Histopathology and molecular biology. World J Gastrointest Surg (2010) 0.81
The secret origins and surprising fates of pancreas tumors. Carcinogenesis (2014) 0.80
Hypermethylation-mediated reduction of WWOX expression in intraductal papillary mucinous neoplasms of the pancreas. Br J Cancer (2009) 0.79
The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Mod Pathol (2016) 0.79
[Precursor lesions of pancreatobiliary cancer]. Pathologe (2011) 0.78
Malignant melanoma arising from a perianal fistula and harbouring a BRAF gene mutation: a case report. BMC Cancer (2011) 0.78
Diagnostic value of combining CA 19-9 and K-ras gene mutation in pancreatic carcinoma: a meta-analysis. Int J Clin Exp Med (2014) 0.77
Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch (2016) 0.76
Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol (2014) 0.75
A new approach to managing intraductal papillary mucinous pancreatic neoplasms. Gut (2007) 0.75
Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med (2016) 0.75
Developmental Pathways Direct Pancreatic Cancer Initiation from Its Cellular Origin. Stem Cells Int (2015) 0.75
Expansion of epigenetic alterations in EFEMP1 promoter predicts malignant formation in pancreatobiliary intraductal papillary mucinous neoplasms. J Cancer Res Clin Oncol (2016) 0.75
Molecular, Histologic, and Radiologic Findings of High-Grade Invasive Adenocarcinoma Arising in Oncocytic Subtype of Intraductal Papillary Mucinous Neoplasm: A Case Report and Review of Literature. J Pancreat Cancer (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res (2002) 4.46
The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell (2001) 3.08
p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res (1997) 2.88
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res (2003) 2.75
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg (2004) 2.62
Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res (2002) 2.48
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer (2003) 2.37
Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J (2000) 2.17
Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia (2005) 2.03
Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab (2003) 1.91
STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol (2001) 1.89
BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res (2003) 1.86
Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer (2002) 1.82
Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis (2003) 1.78
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68
The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol (2002) 1.68
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res (2006) 1.63
Intraductal papillary mucinous neoplasms of the pancreas associated with so-called "mucinous ductal ectasia". Histochemical and immunohistochemical analysis of 29 cases. Am J Surg Pathol (1995) 1.56
Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg (1997) 1.55
Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch (1994) 1.54
Ras gene mutations in intraductal papillary neoplasms of the pancreas. Analysis in five cases. Cancer (1991) 1.47
Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology (2002) 1.32
Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene (2003) 1.32
Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol (1997) 1.29
The "new kid on the block": Intraductal papillary mucinous neoplasms of the pancreas: current concepts and controversies. Surgery (2003) 1.21
Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol (2003) 1.19
Histopathological diagnosis of pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms: interobserver agreement. Pancreas (2005) 1.16
Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann Surg (1993) 1.12
Intraductal papillary tumors and mucinous cystic tumors of the pancreas: clinicopathologic study of 38 cases. Hum Pathol (1997) 1.12
A clinicopathologic and immunohistochemical study of 22 intraductal papillary mucinous neoplasms of the pancreas, with a review of the literature. Mod Pathol (1999) 1.11
c-Ki-ras point mutations in ductectatic-type mucinous cystic neoplasms of the pancreas. Jpn J Cancer Res (1991) 1.07
K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas (1996) 1.04
A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol Cell Biol (2003) 1.03
BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Lett (2003) 0.97
Mutations of BRAF and RAS are rare events in germ cell tumours. Int J Cancer (2005) 0.89
What is the true rate of K-ras mutation in carcinoma of the pancreas? Pancreas (1998) 0.88
The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin-hypersecreting neoplasm of the pancreas. Int J Pancreatol (1993) 0.86
Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst (2003) 3.71
Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics (2003) 3.54
The genetics of colorectal cancer. Ann Intern Med (2002) 2.62
SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene (2003) 2.32
Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res (2010) 1.92
PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 1.90
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res (2006) 1.63
High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res (2013) 1.63
Incidence and predictors of bowel obstruction in elderly patients with stage IV colon cancer: a population-based cohort study. JAMA Surg (2013) 1.57
Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. Tumour Biol (2014) 1.46
Agonist and antagonist recognition by RIG-I, a cytoplasmic innate immunity receptor. J Biol Chem (2008) 1.46
Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun (2007) 1.45
Complete genomic sequence of duck flavivirus from china. J Virol (2012) 1.40
Structure and function of LGP2, a DEX(D/H) helicase that regulates the innate immunity response. J Biol Chem (2008) 1.33
Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis (2006) 1.33
Thyroidectomy using local anesthesia: a report of 1,025 cases over 16 years. J Am Coll Surg (2005) 1.32
The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model. Nat Struct Mol Biol (2007) 1.29
Laparoscopic distal pancreatectomy offers shorter hospital stays with fewer complications. J Gastrointest Surg (2010) 1.28
LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol (2006) 1.28
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol (2013) 1.28
Expression of KIT (CD117) in angiomyolipoma. Am J Surg Pathol (2002) 1.27
MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res (2004) 1.21
Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol (2003) 1.19
Thyroidectomy using monitored local or conventional general anesthesia: an analysis of outpatient surgery, outcome and cost in 1,194 consecutive cases. World J Surg (2006) 1.17
Altered profile of seminal plasma microRNAs in the molecular diagnosis of male infertility. Clin Chem (2011) 1.14
High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis (2002) 1.13
Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer (2008) 1.11
Requirement of IFI16 for the maximal activation of p53 induced by ionizing radiation. J Biol Chem (2004) 1.11
LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res (2003) 1.11
Better preservation of endocrine function after central versus distal pancreatectomy for mid-gland lesions. Surgery (2010) 1.10
Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget (2011) 1.09
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4. Cancer Lett (2006) 1.09
Conditional activin receptor type 1B (Acvr1b) knockout mice reveal hair loss abnormality. J Invest Dermatol (2010) 1.09
Functional interaction of lithocholic acid conjugates with M3 muscarinic receptors on a human colon cancer cell line. Biochim Biophys Acta (2002) 1.07
Risk assessment of heavy metals in soil previously irrigated with industrial wastewater in Shenyang, China. J Hazard Mater (2008) 1.06
Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst (2003) 1.05
Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer (2008) 1.05
Mice that express human interleukin-8 have increased mobilization of immature myeloid cells, which exacerbates inflammation and accelerates colon carcinogenesis. Gastroenterology (2012) 1.05
Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg (2009) 1.04
New monoclonal anti-mouse DC-SIGN antibodies reactive with acetone-fixed cells. J Immunol Methods (2010) 1.03
Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation. AJR Am J Roentgenol (2003) 1.03
Postoperative glycemic control after central pancreatectomy for mid-gland lesions. World J Surg (2007) 1.02
Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. Mol Cancer Ther (2013) 1.02
RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. J Gastrointest Surg (2011) 1.00
Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res (2013) 1.00
Bowel obstruction in elderly ovarian cancer patients: a population-based study. Gynecol Oncol (2012) 0.99
Pancreaticoduodenectomy can be performed safely in patients aged 80 years and older. J Gastrointest Surg (2010) 0.97
Pancreaticogastrostomy: a novel application after central pancreatectomy. J Am Coll Surg (2004) 0.97
Predictive factors of malignancy in pediatric thyroid nodules. Surgery (2011) 0.97
Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis. PLoS One (2012) 0.96
Readmission after pancreatic resection is not an appropriate measure of quality. Ann Surg Oncol (2012) 0.96
One hundred thirty resections for pancreatic neuroendocrine tumor: evaluating the impact of minimally invasive and parenchyma-sparing techniques. J Gastrointest Surg (2010) 0.96
Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Curr Treat Options Gastroenterol (2004) 0.96
Ghrelin inhibits visceral afferent activation of catecholamine neurons in the solitary tract nucleus. J Neurosci (2011) 0.95
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg (2008) 0.94
Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol (2008) 0.94
Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening. J Clin Oncol (2009) 0.93
Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers. Cancer (2011) 0.93
Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol (2013) 0.92
Caffeine-induced activated glucocorticoid metabolism in the hippocampus causes hypothalamic-pituitary-adrenal axis inhibition in fetal rats. PLoS One (2012) 0.92
Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes (2003) 0.92
Defective human MutY phosphorylation exists in colorectal cancer cell lines with wild-type MutY alleles. J Biol Chem (2003) 0.91
Limitations of ACS-NSQIP in reporting complications for patients undergoing pancreatectomy: underscoring the need for a pancreas-specific module. World J Surg (2014) 0.91
Hereditary gingival fibromatosis: a three-generation case and pathogenic mechanism research on progress of the disease. J Periodontol (2010) 0.91
Head and neck squamous cell carcinoma in FAMMM syndrome. Head Neck (2009) 0.91
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival. J Gastrointest Surg (2007) 0.91